Rankings
▼
Calendar
INDV Q3 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena
INDV
Indivior Pharmaceuticals Inc
$4B
Q3 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$307M
+13.3% YoY
Gross Profit
$238M
77.5% margin
Operating Income
$4M
1.3% margin
Net Income
$4M
1.3% margin
EPS (Diluted)
$0.03
QoQ Revenue Growth
+2.7%
Cash Flow
Operating Cash Flow
$8M
Free Cash Flow
-$1M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$1.6B
Stockholders' Equity
-$167M
Cash & Equivalents
$288M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$307M
$271M
+13.3%
Gross Profit
$238M
$225M
+5.8%
Operating Income
$4M
-$183M
+102.2%
Net Income
$4M
-$135M
+103.0%
← FY 2024
All Quarters
Q4 2024 →